[H-].[Na+].[C:3]([C:7]1[CH:12]=[CH:11][C:10]([N:13]2[C:17](=[O:18])[C:16]([CH3:20])([CH3:19])[NH:15][C:14]2=[O:21])=[CH:9][CH:8]=1)([CH3:6])([CH3:5])[CH3:4].Cl[CH2:23][C:24]1[CH:29]=[CH:28][N:27]=[C:26]([S:30][CH3:31])[N:25]=1>O1CCCC1>[C:3]([C:7]1[CH:8]=[CH:9][C:10]([N:13]2[C:17](=[O:18])[C:16]([CH3:20])([CH3:19])[N:15]([CH2:23][C:24]3[CH:29]=[CH:28][N:27]=[C:26]([S:30][CH3:31])[N:25]=3)[C:14]2=[O:21])=[CH:11][CH:12]=1)([CH3:6])([CH3:4])[CH3:5]To a suspension of 1.74 g of sodium hydride (60%) in 70 mL of tetrahydrofuran are successively added, dropwise under an inert atmosphere of argon, a solution of 4.52 g of 3-(4-tert-butylphenyl)-5,5-dimethyl-imidazolidine-2,4-dione obtained in stage c) in 25 mL of tetrahydrofuran, followed by a solution of 5.14 g of 4-(chloromethyl)-2-(methylthio)pyrimidine in 50 mL of tetrahydrofuran. After addition, the reaction mixture is refluxed for 48 hours, cooled to room temperature and poured into distilled water, and the aqueous phase is washed with ethyl acetate. The organic phase is then washed successively with water and saturated sodium chloride solution, dried over magnesium sulphate, filtered and concentrated under reduced pressure. The residue is purified by chromatography on a column of silica, eluting with dichloromethane, to give 5.92 g of 3-(4-tert-butylphenyl)-5,5-dimethyl-1-{[2-(methylthio)pyrimidin-4-yl]methyl}imidazolidine-2,4-dione, the characteristics of which are as follows: